Merck's Bravecto Quantum long-acting flea and tick treatment for dogs approved by FDA.
PorAinvest
viernes, 11 de julio de 2025, 1:45 pm ET1 min de lectura
MRK--
Bravecto Quantum is the first FDA-approved drug to provide such long-lasting protection against fleas and ticks. It is indicated for treating and preventing flea infestations and tick infestations for 12 months in dogs and puppies 6 months of age and older. The product also offers 8 months of protection against Amblyomma americanum (lone star ticks) infestations [1].
The approval of Bravecto Quantum follows its successful introduction in Australia and New Zealand in 2023, and the European Union in 2024. It is now available in more than 50 countries worldwide. Merck Animal Health, a division of Merck & Co., Inc., is excited to offer this convenient, year-long protection against fleas and ticks in a single injection [2].
The FDA has warned that Bravecto Quantum can cause neurological adverse reactions, including muscle tremors, ataxia, and seizures, in some dogs. Therefore, it should only be prescribed by a licensed veterinarian who can properly administer the injection and monitor for adverse reactions [1].
The product is expected to be available at veterinary clinics and hospitals nationwide by August 2025. Merck Animal Health emphasizes that Bravecto Quantum sets a new standard in pet care by providing a safe and effective option for flea and tick protection for dogs.
References:
[1] https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-long-acting-flea-and-tick-treatment-dogs
[2] https://www.marketscreener.com/quote/stock/MERCK-CO-INC-13611/news/Merck-FDA-approval-for-Bravecto-Quantum-50488339/
Merck Animal Health's long-acting flea and tick treatment, Bravecto Quantum, has earned FDA approval for dogs over six months old. The injectable treatment protects against fleas and ticks for 8-12 months and can be used for treating and preventing flea infestations and tick infestations. The FDA warns that the treatment can cause neurological adverse reactions in some dogs. Veterinary clinics will start offering Bravecto Quantum next month.
The U.S. Food and Drug Administration (FDA) has approved Merck Animal Health's Bravecto Quantum (fluralaner for extended-release injectable suspension) for dogs over six months old. This injectable treatment offers 8-12 months of protection against fleas and ticks, making it a significant advancement in veterinary care.Bravecto Quantum is the first FDA-approved drug to provide such long-lasting protection against fleas and ticks. It is indicated for treating and preventing flea infestations and tick infestations for 12 months in dogs and puppies 6 months of age and older. The product also offers 8 months of protection against Amblyomma americanum (lone star ticks) infestations [1].
The approval of Bravecto Quantum follows its successful introduction in Australia and New Zealand in 2023, and the European Union in 2024. It is now available in more than 50 countries worldwide. Merck Animal Health, a division of Merck & Co., Inc., is excited to offer this convenient, year-long protection against fleas and ticks in a single injection [2].
The FDA has warned that Bravecto Quantum can cause neurological adverse reactions, including muscle tremors, ataxia, and seizures, in some dogs. Therefore, it should only be prescribed by a licensed veterinarian who can properly administer the injection and monitor for adverse reactions [1].
The product is expected to be available at veterinary clinics and hospitals nationwide by August 2025. Merck Animal Health emphasizes that Bravecto Quantum sets a new standard in pet care by providing a safe and effective option for flea and tick protection for dogs.
References:
[1] https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-long-acting-flea-and-tick-treatment-dogs
[2] https://www.marketscreener.com/quote/stock/MERCK-CO-INC-13611/news/Merck-FDA-approval-for-Bravecto-Quantum-50488339/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios